CONNECT WITH US
HealthTech

HealthTech

Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment

Medical Xpress logo

Published on

Add as a preferred source on Google
Semaglutide may improve eating disorder symptoms and body image in adults seeking obesity treatment

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Adults receiving semaglutide for obesity treatment experienced greater improvements in several measures of disordered eating, eating disorder symptoms and body image concerns compared with participants receiving placebo, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. The study was published in the International Journal of Eating Disorders.

"Given the growing use of GLP-1 medications for obesity treatment, there has been interest in understanding how these therapies affect disordered eating behaviors and body image," said Kelly Costello Allison, director of Penn's Center for Weight and Eating Disorders (CWED) and the study's first author, who presented findings of the study at ObesityWeek 2026 in Washington, D.C.

"Our findings suggest that semaglutide not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss-of-control eating in many patients," said Jena Tronieri, senior research investigator at Penn's CWED and senior author of the study.

The study included 120 adults seeking treatment for obesity. Participants were randomly assigned to receive either semaglutide 2.4 mg or placebo alongside a structured lifestyle intervention that included dietary counseling and physical activity guidance.

Participants receiving semaglutide experienced substantially greater weight loss than those receiving placebo, losing an average of approximately 15% of their body weight after 60 weeks, compared with about 3% in the placebo group.

Over the course of the 60-week study, participants treated with semaglutide experienced significantly greater improvements in several measures of eating-related and psychological health compared with those receiving placebo.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.